Insider Buying: Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Acquires $25,038.00 in Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Nishant Saxena bought 2,600 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average price of $9.63 per share, with a total value of $25,038.00. Following the transaction, the insider owned 77,900 shares in the company, valued at approximately $750,177. This represents a 3.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Corbus Pharmaceuticals Price Performance

Shares of CRBP stock traded up $0.25 on Wednesday, hitting $9.76. 548,769 shares of the stock traded hands, compared to its average volume of 329,271. The company has a market capitalization of $182.22 million, a PE ratio of -1.58 and a beta of 2.59. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $7.12 and a 1-year high of $20.56. The company’s fifty day moving average is $8.79 and its 200 day moving average is $9.06.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, equities research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 EPS for the current year.

Key Headlines Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target for Corbus Pharmaceuticals, well above recent trading levels. The firm’s institutional ownership is also substantial, with several hedge funds increasing their positions, which may provide support for the stock. Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals Stock
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the data also shows an invalid “NaN” percentage change, it offers little meaningful insight into current trading pressure.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of losses of $6.11 per share for 2026, $6.83 for 2027, $5.56 for 2028 and $2.07 for 2029. Its 2030 forecast was cut sharply to $0.15 from $1.29, indicating a slower path to profitability. HC Wainwright Estimate Changes for Corbus Pharmaceuticals
• Negative Sentiment: Company insiders sold shares: CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at an average price of $10.08. Although both executives retained sizable holdings, the sales reduce their positions by approximately 9.75% and 12.41%, respectively, potentially weighing on sentiment. Corbus Pharmaceuticals CFO SEC Filing
• Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate by $0.55. The clinical-stage company’s high beta and lack of current earnings leave CRBP particularly sensitive to clinical, financing and forecast-related news.

Analyst Ratings Changes

Several research analysts have recently commented on CRBP shares. HC Wainwright decreased their price target on shares of Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating for the company in a report on Friday, August 7th. Mizuho cut their target price on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating on the stock in a report on Tuesday, June 23rd. Guggenheim reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals in a report on Tuesday, May 26th. Jefferies Financial Group cut their price target on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Finally, Oppenheimer reduced their price objective on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.12.

Institutional Trading of Corbus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in Corbus Pharmaceuticals during the 2nd quarter valued at about $425,000. Seven Fleet Capital Management LP increased its stake in shares of Corbus Pharmaceuticals by 51.0% in the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 28,937 shares during the period. Bank of America Corp DE raised its holdings in shares of Corbus Pharmaceuticals by 53,592.3% during the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 13,934 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Corbus Pharmaceuticals by 81.2% during the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 13,401 shares during the last quarter. Finally, Exome Asset Management LLC boosted its position in shares of Corbus Pharmaceuticals by 67.8% during the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock worth $2,199,000 after buying an additional 94,593 shares during the period. 64.64% of the stock is currently owned by institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.